| Description |
1 online resource |
| Contents |
Front Cover -- Cardiovascular Endocrinology & -- Metabolism -- Copyright Page -- Contents -- List of contributors -- Foreword -- Introduction -- 1 Basic science and pathophysiology -- 1 Obesity and insulin resistance: routes to vascular disease -- Insulin and atherosclerosis -- Adipocyte-nonesterified fatty acids -- Macrophage-inflammatory signaling-adipokines -- Dyslipidemia -- Hypertension -- Type 2 diabetes -- Mitochondrial stress, endoplasmic reticulum stress, and oxidative stress -- Summary -- References -- 2 Diabetes mellitus and macrovascular disease: epidemiology and cardiovascular risk assessment -- Introduction -- Epidemiology -- Epidemiology of diabetes mellitus -- Epidemiology of macrovascular diseases in diabetes mellitus -- Coronary artery disease -- Cerebrovascular diseases -- Peripheral artery disease in diabetes mellitus -- Cardiovascular disease risk assessment in diabetes mellitus -- Cardiovascular risk factors in persons with diabetes -- Obesity -- Dyslipidemia -- Hypertension -- Lifestyle factors -- Cardiovascular risk factor control and outcomes -- Conclusion -- References -- 3 Complex metabolic-endocrine syndromes: associations with cardiovascular disease -- Introduction -- Metabolic syndrome -- Metabolic fatty liver disease -- Immunity, inflammation, and oxidative stress -- Role of lymphatic system and metabolic disease -- Diabetes mellitus -- Type 2 diabetes -- Vascular disease in type 2 diabetes -- Role of pharmacotherapy for type 2 diabetes -- Type 1 diabetes -- Cardiometabolic risk factors in type 1 diabetes -- Treatment-insulin replacement and cardiovascular risk management -- Polycystic ovary syndrome -- Polycystic ovary syndrome and cardiometabolic risk -- Management -- Male hypogonadism -- Testosterone and type 2 diabetes in men -- Testosterone, erectile dysfunction, and cardiovascular risk |
|
Testosterone therapy: risks and benefits -- Future prospects: toward more personalized management of metabolic-endocrine-cardiovascular disorders -- References -- 4 Hypertension: pathophysiology and relevance to the cardiometabolic syndrome -- Pathophysiology of hypertension in cardiometabolic syndrome -- Arterial system -- Endothelial dysfunction -- Arteriolar remodeling -- Large artery stiffening -- Regulatory systems -- Sympathetic nervous system activation -- Abnormal renal sodium handling -- Renin-angiotensin-aldosterone system activation -- Implications of pathophysiology for treatment of hypertension -- The importance of primordial prevention of metabolic syndrome from early life -- Conclusion -- References -- 5 Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics -- Introduction -- Lipoprotein metabolism -- Lipids and atherosclerotic cardiovascular disease -- Lipid-lowering therapy and atherosclerotic cardiovascular disease -- Low-density lipoprotein-lowering: therapeutic options -- Statins -- Ezetimibe -- Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies -- Inclisiran -- Bempedoic acid -- Other lipid-lowering drugs -- Triglyceride-lowering medications -- Therapeutic targets for high-density lipoprotein-cholesterol -- Safety of very low low-density lipoprotein-cholesterol levels -- Understanding the benefits of low-density lipoprotein-cholesterol lowering: NNT and N100 -- Lipids and microvascular disease -- Retinopathy -- Lipid-lowering therapy and retinopathy -- Neuropathy -- Lipid-lowering therapy and neuropathy -- Nephropathy -- Lipid-lowering therapy and nephropathy -- Conclusion -- Note added in proof -- References -- 6 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular di... -- Introduction |
|
Potential mechanisms underlying nonalcoholic fatty liver disease and cardiovascular diseases -- Insulin resistance -- Intrahepatic lipid accumulation -- Inflammation and oxidative stress -- Adiponectin -- Atherogenic dyslipidemia -- Postprandial hyperlipidemia -- Obstructive sleep apnea -- Influence on hemostatic-fibrinolytic factors -- Intestinal microbiome -- Altered bile acid metabolism -- Association between nonalcoholic fatty liver disease and cardiovascular disease -- Coronary artery disease -- Carotid artery disease -- Cardiac arrhythmias and conduction defects -- Epicardial adipose tissue, cardiac remodeling, cardiomyopathy -- Heart valve calcification -- Treatment strategies -- Lifestyle measures and weight loss -- Diet -- Pharmacological interventions for weight loss -- Insulin resistance and diabetes -- Acetylsalicyclic acid -- Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers -- Antioxidants -- Lipid-lowering therapy in atherogenic dyslipidemia -- Endoscopic and surgical options -- Conclusion -- References -- 7 Cardiac energy metabolism in heart failure -- Introduction -- Energy metabolism in the normal heart -- Fatty acid ß-oxidation -- Carbohydrate metabolism -- Ketone metabolism -- Branched-chain amino acid oxidation -- Cardiac energy metabolism in heart failure with reduced ejection fraction -- Fatty acid metabolism in heart failure with reduced ejection fraction -- Glucose metabolism in heart failure with reduced ejection fraction -- Ketone oxidation in heart failure with reduced ejection fraction -- Branched-chain amino acid oxidation in heart failure with reduced ejection fraction -- Cardiac energy metabolism in heart failure with preserved ejection fraction -- Fatty acid oxidation in heart failure with preserved ejection fraction -- Glucose metabolism in heart failure with preserved ejection fraction |
|
Ketone body and branched-chain oxidation in heart failure with preserved ejection fraction -- Branched-chain amino acid oxidation in heart failure with preserved ejection fraction -- Therapeutic opportunities -- Inhibiting fatty acid oxidation -- Stimulating glucose oxidation -- Stimulating ketone oxidation -- Stimulating branched-chain amino acid oxidation -- Conclusion -- References -- 8 Hemostatic abnormalities associated with diabetes and their clinical implications -- Introduction -- The role of thrombosis in acute coronary syndromes -- Hemostatic mechanisms -- The coagulation system -- Thrombin -- Factor VII -- Fibrinogen -- Factor XII -- Factor XIII -- The fibrinolytic system -- Plasmin generation -- Plasminogen activator inhibitor-1 -- Tissue plasminogen activator -- Function of fibrin structure in type 2 diabetes -- Platelets and type 2 diabetes -- Reticulated platelets -- The effects of chronic renal insufficiency -- Implications for therapeutic approaches to vascular disease in diabetes -- Primary prevention -- Secondary prevention -- Coronary artery disease -- Cerebrovascular disease -- Peripheral arterial disease -- Summary and conclusion -- Acknowledgments -- References -- 9 Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction -- Introduction -- From epidemiological associations to causal relationships -- Association of causal relationship? A call for intervention studies -- Intervention trials to lower HbA1c: impact on cardiovascular events -- Legacy effect-do we need more time to see beneficial effects of improved glycemic control? -- Different background medications in the various trials of intensive glucose lowering -- New glucose-lowering agents show cardio-renal benefit in high-risk patients -- A change in the paradigm of cardio-renal protection for type 2 diabetes |
|
Multiple cardiovascular risk factors are often present in people with type 2 diabetes -- Potential and emerging interventions -- Implications for the clinical management of type 2 diabetes -- References -- 10 Classic endocrine disorders: implications for cardiovascular disease -- Introduction -- Thyroid -- Hyperthyroidism -- Hypothyroidism -- Subclinical hypothyroidism -- Parathyroids -- Hyperparathyroidism -- Hypoparathyroidism -- Pituitary -- Acromegaly -- Growth hormone deficiency -- Prolactinoma -- Adrenal -- Cushing's syndrome -- Hypoadrenalism -- Conn's syndrome -- Pheochromocytoma -- Islets of Langerhans -- Insulinoma -- Glucagonoma -- References -- 2 Clinical evaluation, lifestyle measures and therapeutic options -- 11 The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and s... -- Introduction: cardiometabolic disease, obesity, and residual risk of cardiovascular disease -- Fundamental role of obesity and insulin resistance in cardiometabolic disease and cardiovascular disease risk -- The pathophysiology of obesity -- Obesity complications -- Adiposity-based chronic disease -- Obesity and cardiometabolic disease -- Insulin resistance, type 2 diabetes, and cardiovascular disease: a pathogenic triad -- Treatment of adiposity-based chronic disease/obesity -- Clinical practice guidelines and complications-centric approach to care -- Disease staging -- Treatment of adiposity-based chronic disease/obesity: lifestyle therapy, pharmacotherapy, and bariatric procedures -- Lifestyle therapy -- Pharmacotherapy -- Bariatric surgery procedures -- Role of weight loss therapy for treatment and prevention in cardiometabolic disease -- Treatment goals -- Comprehensive risk factor management -- Benefits of weight loss in adiposity-based chronic disease and cardiometabolic disease |
| Summary |
Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine discusses the close intersection between metabolic disorders and cardiovascular disease, covering the basic science and pathophysiology of disease and the latest research in pharmacological approaches and translational therapeutic options. This book is a valuable resource for the vascular and endocrinology clinical and research communities in need of knowledge and potential outcomes. The global increase in the prevalence of cardiometabolic disorders, and the introduction of therapeutic options for treating metabolic disease that also lower cardiovascular risk, is bringing endocrinologists and cardiologists together in a shared clinical experience. Discusses the intersection between metabolic disorders and cardiovascular diseases Provides a comprehensive understanding of the relevant pathophysiology of diseases as a basis for the evidence-based management of cardiometabolic disorders Offers a comprehensive reference, ranging from basic science and pathophysiology to clinical diagnostics and management |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based on online resource; title from digital title page (viewed on December 19, 2023) |
| Subject |
Cardiovascular system -- Diseases -- Endocrine aspects
|
|
Cardiovascular system -- Diseases -- Mortality.
|
| Form |
Electronic book
|
| ISBN |
0323983189 |
|
9780323983181 |
|
